ACB
Price
$5.39
Change
-$0.10 (-1.82%)
Updated
May 23, 10:59 AM (EDT)
Capitalization
238.86M
27 days until earnings call
CRON
Price
$2.02
Change
-$0.05 (-2.42%)
Updated
May 23, 12:01 PM (EDT)
Capitalization
1B
76 days until earnings call
Interact to see
Advertisement

ACB vs CRON

Header iconACB vs CRON Comparison
Open Charts ACB vs CRONBanner chart's image
Aurora Cannabis
Price$5.39
Change-$0.10 (-1.82%)
Volume$1K
Capitalization238.86M
Cronos Group
Price$2.02
Change-$0.05 (-2.42%)
Volume$100
Capitalization1B
ACB vs CRON Comparison Chart
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. CRON commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and CRON is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (ACB: $5.49 vs. CRON: $2.07)
Brand notoriety: ACB: Notable vs. CRON: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACB: 79% vs. CRON: 0%
Market capitalization -- ACB: $238.86M vs. CRON: $1B
ACB [@Pharmaceuticals: Other] is valued at $238.86M. CRON’s [@Pharmaceuticals: Other] market capitalization is $1B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileCRON’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • CRON’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACB and CRON are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 5 TA indicator(s) are bullish while CRON’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 5 bullish, 4 bearish.
  • CRON’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ACB and CRON are a good buy in the short-term.

Price Growth

ACB (@Pharmaceuticals: Other) experienced а +10.69% price change this week, while CRON (@Pharmaceuticals: Other) price change was -0.48% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.07%. For the same industry, the average monthly price growth was +8.64%, and the average quarterly price growth was +29.32%.

Reported Earning Dates

ACB is expected to report earnings on Aug 07, 2025.

CRON is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.07% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRON($1.01B) has a higher market cap than ACB($239M). ACB YTD gains are higher at: 29.176 vs. CRON (2.475). CRON has higher annual earnings (EBITDA): -71.8M vs. ACB (-1.64B). CRON has more cash in the bank: 862M vs. ACB (149M). CRON has less debt than ACB: CRON (2.55M) vs ACB (103M). ACB has higher revenues than CRON: ACB (212M) vs CRON (87.2M).
ACBCRONACB / CRON
Capitalization239M1.01B24%
EBITDA-1.64B-71.8M2,280%
Gain YTD29.1762.4751,179%
P/E RatioN/AN/A-
Revenue212M87.2M243%
Total Cash149M862M17%
Total Debt103M2.55M4,034%
FUNDAMENTALS RATINGS
ACB vs CRON: Fundamental Ratings
ACB
CRON
OUTLOOK RATING
1..100
2021
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8983
PRICE GROWTH RATING
1..100
4748
P/E GROWTH RATING
1..100
6871
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRON's Valuation (55) in the Pharmaceuticals Other industry is in the same range as ACB (58). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

CRON's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ACB (100). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

CRON's SMR Rating (83) in the Pharmaceuticals Other industry is in the same range as ACB (89). This means that CRON’s stock grew similarly to ACB’s over the last 12 months.

ACB's Price Growth Rating (47) in the Pharmaceuticals Other industry is in the same range as CRON (48). This means that ACB’s stock grew similarly to CRON’s over the last 12 months.

ACB's P/E Growth Rating (68) in the Pharmaceuticals Other industry is in the same range as CRON (71). This means that ACB’s stock grew similarly to CRON’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBCRON
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 8 days ago
70%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GIIAX9.88N/A
N/A
Nationwide International Index A
SIDVX11.86N/A
N/A
Hartford Schroders Intl Multi-Cp Val A
AGIRX18.18N/A
N/A
Alger Mid Cap Growth Institutional R
RMCFX9.70N/A
N/A
Royce Micro-Cap Svc
ACIHX59.18N/A
N/A
American Century Growth G